Grunenthal GmbH - Strategic SWOT Analysis Review

Grunenthal GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company that researches, develops and markets products for the treatment of pain management and related diseases. Its portfolio includes a wide range of medicinal products for chronic and acute pain, nociceptive and neuropathic pain. The company’s products portfolio include Tramal used for the treatment of moderate to severe pain; Transtec used to treat moderate to severe cancer pain; and Vimovo used for the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. The company distributes products and operates in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Nordrhein-Westfalen, Germany.

Grunenthal GmbH Key Recent Developments

Apr 27,2023: Grunenthal and King's College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research
Mar 27,2023: Grünenthal reports record revenue and profit in 2022 full-year results and strong pipeline progress
Mar 30,2022: Grunenthal announces reports 2021 full-year results
Mar 07,2022: Grünenthal donates 400.000€ and provides pain treatment medicine to Ukraine

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note:Some sections may be missing if data is unavailable for the company.